Official PDF Translation•Stem Cell Research & Therapy

Correction: Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial

Authors: Masao Koda; Shiro Imagama; Hiroaki Nakashima; Sadayuki Ito; Naoki Segi; Jun Ouchida; Kota Suda; Satoko Harmon Matsumoto; Miki Komatsu; Toshiki Endo; Shinsuke Suzuki; Satoshi Inami; Haruki Ueda; Masayuki Miyagi; Gen Inoue; Masashi Takaso; Keiji Nagata; Hiroshi Yamada; Naosuke Kamei; Toshio Nakamae; Hidenori Suzuki; Norihiro Nishida; Masahiro Funaba; Gentaro Kumagai; Takeo Furuya; Yu Yamato; Toru Funayama; Hiroshi Takahashi; Masashi Yamazaki

DOI: 10.1186/s13287-024-04044-0Status: Verified Translated Edition

Sponsored AdvertisementAd Placement Area

reCAPTCHA Bot Shield Active

Preparing Secure Academic Download

Verifying human reader & generating high-resolution document...

Verifying Document Integrity15s remaining

← Back to Article

Protected by Google reCAPTCHA v3.•Privacy•Terms

Sponsored ContentAdSense In-Feed Ad Slot

Key Findings in This Report

• This correction addresses two errors in the original article: a sentence on page 3 and a Y-axis label in Fig. 2C. • The correction clarifies the interpretation of B1 and B2 as indicating complete data, removing the ambiguous '(Ref)'. • The Y-axis label in Fig. 2C is corrected to 'Change in total motor score', removing the word 'lower'. • These corrections ensure accurate reporting of the clinical trial results on allogenic-Muse cell therapy for cervical spinal cord injury.